Form 8-K - Current report:
SEC Accession No. 0001213900-25-065162
Filing Date
2025-07-17
Accepted
2025-07-17 16:33:25
Documents
15
Period of Report
2025-07-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0249410-8k_nkgen.htm   iXBRL 8-K 33051
2 COLLABORATION AGREEMENT, DATED JULY 14, 2025, BY AND BETWEEN NKGEN BIOTECH, INC. ea024941001ex10-1_nkgen.htm EX-10.1 417772
3 PRESS RELEASE, DATED JULY 17, 2025 ea024941001ex99-1_nkgen.htm EX-99.1 13669
  Complete submission text file 0001213900-25-065162.txt   776684

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nkgn-20250714.xsd EX-101.SCH 3881
5 XBRL DEFINITION FILE nkgn-20250714_def.xml EX-101.DEF 26778
6 XBRL LABEL FILE nkgn-20250714_lab.xml EX-101.LAB 37007
7 XBRL PRESENTATION FILE nkgn-20250714_pre.xml EX-101.PRE 25402
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0249410-8k_nkgen_htm.xml XML 5591
Mailing Address 3001 DAIMLER ST, SANTA ANA CA 92705
Business Address 3001 DAIMLER ST, SANTA ANA CA 92705 (949) 396-6830
NKGen Biotech, Inc. (Filer) CIK: 0001845459 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40427 | Film No.: 251131037
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)